Today, on World Sight Day, the first patient was screened for diabetic retinopathy at the Baton Rouge Clinic using the new Verily Retinal Service. Diabetic Retinopathy is the leading cause of preventable blindness among working-age adults in the United States1. For these patients, early diagnosis and treatment by clinicians is critical, however, 40% miss their annual screening2.
Empowering providers & patients to stay ahead of diabetic retinopathy
To boost screening rates, Verily and The Baton Rouge Clinic deployed the new Verily Retinal Service in the Baton Rouge community—an intuitive solution that combines hardware, software and services to expand access to quality eye screening.
Born out of a real-world need and a long-standing collaboration between Google and Verily, the Verily Retinal Service aims to prevent blindness by combining an easy to operate, patient-friendly fundus camera (Verily Retinal Camera), with end-to-end workflow software (Verily Retinal Platform). This combination requires minimal operator training and enables seamless integration with clinical workflows.
"When advancements in technology are coupled with talented physicians, lives can be changed for the better. The Baton Rouge Clinic, AMC is committed to caring for this community and today we are thrilled to be able to bring the latest state of the art technology to Baton Rouge in the form of the new Verily Retinal Service. We are hopeful that with this device we can offer another platform to detect disease earlier and prevent blindness in diabetic patients so that they can continue to see the beauty of Baton Rouge." - Shunn Phillips, Chief Financial Officer at Baton Rouge Clinic
Bringing advanced technology in eye health to expand access
The first patient screened at the Baton Rouge Clinic represents an important step in making more preventive screening services available in primary care settings.
“We are excited to partner with the Baton Rouge Clinic to leverage the power of technology to improve access to care in their community. We could not have asked for a better partner in our latest efforts to tackle the issue of diabetic retinopathy.” - Dr. Vindell Washington, Chief Clinical Officer, Verily Health Platforms
Regarding the future, David Barkin, Director of Product Management and Head of the Verily Retinal Service, states that "going forward, Verily and Baton Rouge Clinic remain focused on expanding our joint efforts to increase access to diabetic retinopathy screening to as many people as possible."
For more information on the product and services, please visit the Verily website.